KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organon (OGN) Invested Capital (2020 - 2026)

Organon has reported Invested Capital over the past 7 years, most recently at $9.5 billion for Q1 2026.

  • For Q1 2026, Invested Capital changed 0.27% year-over-year to $9.5 billion; the TTM value through Mar 2026 reached $9.5 billion, changed 0.27%, while the annual FY2025 figure was $9.4 billion, 0.47% changed from the prior year.
  • Invested Capital for Q1 2026 was $9.5 billion at Organon, up from $9.4 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $9.7 billion in Q3 2025 and troughed at $7.6 billion in Q3 2022.
  • A 5-year average of $8.7 billion and a median of $8.8 billion in 2024 define the central range for Invested Capital.
  • On a YoY basis, Invested Capital climbed as much as 25.76% in 2022 and fell as far as 0.64% in 2022.
  • Year by year, Invested Capital stood at $8.0 billion in 2022, then grew by 8.34% to $8.7 billion in 2023, then grew by 7.62% to $9.4 billion in 2024, then rose by 0.47% to $9.4 billion in 2025, then increased by 0.81% to $9.5 billion in 2026.
  • Business Quant data shows Invested Capital for OGN at $9.5 billion in Q1 2026, $9.4 billion in Q4 2025, and $9.7 billion in Q3 2025.